Anthony Lowell, Bowen Joanne, Garden Adam, Hewson Ian, Sonis Stephen
The Stanley S. Scott Cancer Center, LSUHSC, New Orleans, LA, USA.
Support Care Cancer. 2006 Jun;14(6):516-8. doi: 10.1007/s00520-006-0058-1. Epub 2006 Apr 1.
Our understanding of the biological basis for mucosal barrier injury (mucositis) induced by cancer therapy with radiation or drugs continues to evolve. A patient's mucosal response to cancer therapy appears to be controlled by both global (i.e. gender, underlying systemic disease, race) and tissue specific (i.e. epithelial type, intrinsic endocrine system, local microbial environment, function) factors.
Interactions of these elements, coupled with underlying genetic influences, most likely govern the risk, course and severity of regimen-related mucosal injury.
我们对放疗或药物等癌症治疗引起的黏膜屏障损伤（黏膜炎）的生物学基础的理解仍在不断发展。患者对癌症治疗的黏膜反应似乎受整体因素（如性别、潜在的全身性疾病、种族）和组织特异性因素（如上皮类型、内在内分泌系统、局部微生物环境、功能）的控制。
这些因素的相互作用，再加上潜在的遗传影响，很可能决定了与治疗方案相关的黏膜损伤的风险、病程和严重程度。
